Pasquale Pisapia1, Francesco Pepe1, Anna Baggi2, Massimo Barberis3, Antonio Galvano4, Valerio Gristina4, Fabrizio Mastrilli5, Silvia Novello6, Fabio Pagni7, Silvia Pasini2, Giuseppe Perrone8, Daniela Righi8, Antonio Russo4, Giancarlo Troncone1, Umberto Malapelle9. 1. Department of Public Health, University of Naples Federico II, Naples, Italy. 2. Business Integration Partners (BIP), Life Sciences Division, Italy. 3. Unit of Histopathology and Molecular Diagnostics, Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy. 4. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy. 5. Medical Director, IEO, European Institute of Oncology, IRCCS, Milan, Italy. 6. Department of Oncology, San Luigi Hospital, University of Turin, Orbassano, Italy. 7. Department of Pathology, University of Milan-Bicocca (UNIMIB), 20900, Monza, Italy. 8. Predictive Molecular Diagnostic Division, Department of Pathology, Campus Bio-Medico, University of Rome, Italy. 9. Department of Public Health, University of Naples Federico II, Naples, Italy. Electronic address: umberto.malapelle@unina.it.
Abstract
AIMS: The KWAY project aims to investigate the economic sustainability of the up-front NGS technologies adoption in the analysis of clinically relevant molecular alterations in NSCLC patients. METHODS: The diagnostic workflow and the related sustained costs of five Italian referral centers were assessed in four different evolving scenarios were analyzed. For each scenario, two alternative testing strategies were evaluated: the Maximized Standard strategy and the Maximized NGS strategy. RESULTS: For each center, the robustness of obtained results was verified through a deterministic sensitivity analysis, observing the variation of total costs based on a variation of ±20 % of the input parameters and ensuring that results would present a consistent behavior compared to the original ones. CONCLUSIONS: our project, highlighted that the adoption of NGS allows to save personnel time dedicated to testing activities and to reduce the overall cost of testing per patient.
AIMS: The KWAY project aims to investigate the economic sustainability of the up-front NGS technologies adoption in the analysis of clinically relevant molecular alterations in NSCLC patients. METHODS: The diagnostic workflow and the related sustained costs of five Italian referral centers were assessed in four different evolving scenarios were analyzed. For each scenario, two alternative testing strategies were evaluated: the Maximized Standard strategy and the Maximized NGS strategy. RESULTS: For each center, the robustness of obtained results was verified through a deterministic sensitivity analysis, observing the variation of total costs based on a variation of ±20 % of the input parameters and ensuring that results would present a consistent behavior compared to the original ones. CONCLUSIONS: our project, highlighted that the adoption of NGS allows to save personnel time dedicated to testing activities and to reduce the overall cost of testing per patient.